BGNE - BeiGene, Ltd.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
-0.27 (-0.29%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close93.87
Bid0.00 x 0
Ask0.00 x 0
Day's Range92.15 - 95.50
52 Week Range27.89 - 118.95
Avg. Volume341,690
Market Cap3.959B
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • China biotech's 'coming out party' masks long road ahead
    Reuters2 months ago

    China biotech's 'coming out party' masks long road ahead

    LONDON/SHANGHAI (Reuters) - Investors are betting on China's potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West. Shares in firms such as Chi-Med (LSE:HCM.L - News), Beigene (NasdaqGS:BGNE - News) and Zai Lab (NasdaqGM:ZLAB - News) have soared on international markets this year, fueled by hopes for their drugs and recent reforms to China's regulatory system that should speed up approvals. "It's almost a coming out party for China biotech," said Christian Hogg, chief executive of Hutchison China MediTech or Chi-Med, which presented promising data at a global medical congress this week on a lung cancer drug it discovered in China and is developing with AstraZeneca (LSE:AZN.L - News).

  • Barrons.com3 months ago

    [$$] Celgene Invests in Acceleron, BeiGene

    Celgene doesn’t let a partner down. The biotech on Monday bought 750,000 more shares of Acceleron (XLRN) for $28 million in a public stock offering. Celgene (CELG) remains Acceleron’s largest holder and is a partner for the latter’s lead program, Luspatercept, and for sotatercept.

  • We're sorry this is all we were able to find about this topic.